FREE STANDARD SHIPPING ON ORDERS $250+

BPC-157 10mg

From $86.40

Shop

BPC-157 10mg · Research brief

BPC-157 IU Per Tick Insulin Syringe — Dosing Precision

RP
Real Peptides Research TeamEditorial
Updated April 22, 20269 min read
60 WORDS

Short answer

Research from institutions like the University of Zagreb has demonstrated BPC-157 's regenerative properties in preclinical models—but none of that matters if the dose reaching tissue is 40% lower than intended because the reconstitution math was wrong. The single biggest dosing mistake we see in research protocols isn't injection technique or storage—it's the assumption that 'one tick on the syringe'…

Key takeaways

  • A standard 1mL insulin syringe holds 100 IU total, with each tick representing 1 IU or 0.01mL—the actual BPC-157 dose per tick depends entirely on reconstitution concentration.
  • Reconstituting 5mg BPC-157 in 2mL bacteriostatic water yields 2.5mg/mL concentration, delivering 25mcg of peptide per 1 IU tick on the syringe.
  • Insulin syringes eliminate dead space found in Luer-lock syringes, ensuring full dose delivery with <0.005mL residual loss—critical for precision at research doses of 200–500mcg.
  • Reconstitution at refrigerated temperature (2–8°C) and slow addition of bacteriostatic water down the vial wall prevents peptide denaturation and foam formation that distorts volume measurements.
  • Concentrations above 5mg/mL reduce injection volume but push small doses into the 3–5 tick range, where syringe reading accuracy drops and air bubbles introduce proportionally larger errors.

Research from institutions like the University of Zagreb has demonstrated BPC-157's regenerative properties in preclinical models—but none of that matters if the dose reaching tissue is 40% lower than intended because the reconstitution math was wrong. The single biggest dosing mistake we see in research protocols isn't injection technique or storage—it's the assumption that 'one tick on the syringe' translates to a fixed peptide dose regardless of how the vial was mixed.

Our team works with researchers who use BPC-157 across tissue repair studies, gut inflammation models, and tendon healing protocols. The gap between accurate dosing and guesswork comes down to understanding that insulin syringes measure volume in international units (IU), not peptide mass in micrograms—and converting between the two requires knowing your exact reconstitution concentration.

How many IU per tick are in a BPC-157 insulin syringe?

A standard 1mL (100-unit) insulin syringe contains 100 IU total volume, with each small tick representing 1 IU or 0.01mL. The actual BPC-157 dose per tick depends entirely on reconstitution concentration—5mg BPC-157 in 2mL bacteriostatic water yields 50mcg per 1 IU tick, while the same 5mg in 1mL yields 100mcg per tick.

Here's what most guides skip: insulin syringes don't measure peptide mass—they measure liquid volume in international units (1 IU = 0.01mL). The peptide concentration you create during reconstitution determines how many micrograms of BPC-157 are in each IU of volume. A 5mg vial mixed with 2mL of bacteriostatic water creates a 2.5mg/mL solution—meaning each 0.01mL (1 IU tick) contains 25mcg of BPC-157. The same vial mixed with 1mL creates a 5mg/mL solution, doubling the peptide dose per tick to 50mcg. This article covers how to calculate BPC-157 IU per tick insulin syringe doses accurately, why reconstitution ratio is the single most important variable, and what preparation errors negate dosing precision entirely.

Calculating BPC-157 Dose Per Syringe Tick

The formula for determining BPC-157 IU per tick insulin syringe dose is straightforward: divide total peptide mass (mg) by reconstitution volume (mL) to get concentration, then multiply by 0.01mL (the volume of one tick). A 5mg vial reconstituted in 2mL bacteriostatic water yields 2.5mg/mL concentration—each 1 IU tick contains 25mcg of BPC-157. The same 5mg vial in 1mL yields 5mg/mL concentration, delivering 50mcg per tick.

Researchers often default to '2mL per vial' without considering protocol requirements. A 250mcg daily dose at 2.5mg/mL concentration requires 10 ticks (0.1mL)—manageable with a standard insulin syringe. The same 250mcg dose at 5mg/mL concentration requires only 5 ticks (0.05mL), reducing injection volume but increasing the margin for measurement error at small tick counts. Higher concentrations allow smaller injection volumes but demand more precise syringe reading—below 5 ticks, even slight hand tremor introduces meaningful variability.

We've found that 2–2.5mL reconstitution volume per 5mg vial balances usability and precision. It produces concentrations where typical research doses (200–500mcg) fall within 8–20 ticks—a range where insulin syringe graduations remain visually distinct and measurement error stays below 5%. Concentrations above 5mg/mL save liquid volume but push small doses into the 3–5 tick range, where reading accuracy drops and air bubbles become proportionally more significant.

Reconstitution Variables That Alter Dosing Accuracy

Bacteriostatic water is the standard reconstitution solvent for lyophilised BPC-157, containing 0.9% benzyl alcohol as a preservative to inhibit bacterial growth over multi-dose use. Sterile water for injection (SWFI) lacks preservative and must be used within 24 hours of reconstitution—practical only for single-use protocols. Using non-bacteriostatic water in a multi-dose vial introduces contamination risk that compounds with each needle puncture.

Temperature during reconstitution affects dissolution completeness. BPC-157 lyophilised powder dissolves most predictably when both the vial and bacteriostatic water are at 2–8°C (refrigerated). Reconstituting at room temperature accelerates dissolution but can create localised concentration gradients if the vial isn't gently swirled—shaking introduces air bubbles that displace liquid volume and distort dose measurements. We recommend refrigerating the sealed vial and the bacteriostatic water ampule for 30 minutes before mixing, then allowing the reconstituted solution to reach room temperature before drawing the first dose.

The order of operations matters: inject bacteriostatic water slowly down the inside wall of the vial—never directly onto the lyophilised puck. Direct impact can denature surface peptides and create foam that takes 10–15 minutes to settle. Once water is added, swirl gently in circular motions for 60–90 seconds until the solution is clear. Cloudiness or visible particles after two minutes of gentle swirling suggests incomplete dissolution or peptide aggregation—both compromise dosing accuracy.

Why Standard Insulin Syringes Are Used for BPC-157

Insulin syringes are purpose-built for subcutaneous injection of small liquid volumes with high precision. A standard 1mL (100-unit) insulin syringe features 100 graduations, each representing 0.01mL or 1 IU—making it ideal for peptide protocols where doses range from 0.05mL to 0.5mL. The needle gauge (typically 29–31G) and length (8–12.7mm) are optimised for subcutaneous deposition into adipose tissue without reaching muscle.

BPC-157 research doses typically fall between 200mcg and 500mcg per administration. At a 2.5mg/mL reconstitution concentration, this translates to 0.08mL (8 ticks) to 0.2mL (20 ticks)—well within the readable range of insulin syringe graduations. Larger syringes (3mL or 5mL) intended for intramuscular injection have wider graduation spacing (0.1mL or 0.2mL per tick), making sub-0.1mL measurements impractical.

The fixed needle design of insulin syringes eliminates the dead space found in Luer-lock syringes, where 0.02–0.05mL of solution remains in the hub after injection. For protocols requiring precision within ±10mcg, dead space loss represents 4–20% of a 250mcg dose—an unacceptable margin in controlled research. Insulin syringes deliver the full drawn volume with <0.005mL residual loss.

[Full Keyword]: Syringe Type Comparison

Understanding BPC-157 IU per tick insulin syringe dosing requires comparing syringe types and their impact on measurement precision.

Syringe Type Total Volume Graduation Increment Suitable Dose Range Needle Specs Dead Space Professional Assessment
1mL Insulin Syringe (100 IU) 1mL (100 IU) 1 IU (0.01mL) 50–500mcg BPC-157 at typical concentrations 29–31G, 8–12.7mm <0.005mL Optimal for subcutaneous peptide dosing—graduations allow ±5mcg precision at research-relevant doses. Fixed needle eliminates dead space.
0.5mL Insulin Syringe (50 IU) 0.5mL (50 IU) 0.5 IU (0.005mL) 25–250mcg at high concentrations 29–31G, 8mm <0.005mL Best precision for ultra-low doses—each tick is half the volume of standard syringes, but maximum capacity limits use to high-concentration solutions (>5mg/mL).
3mL Luer-Lock Syringe 3mL 0.1mL 1mg+ doses only Detachable, varies 0.02–0.05mL Unsuitable for BPC-157 research dosing—graduation spacing too wide for sub-0.1mL accuracy, and dead space causes significant dose loss.
Tuberculin Syringe (1mL) 1mL 0.01mL 50–500mcg 26–27G, 12.7–15.9mm 0.01–0.02mL Accurate but needle length exceeds optimal subcutaneous depth—designed for intradermal injection, not adipose deposition.

What If: BPC-157 Dosing Scenarios

What If I Draw Air Bubbles Into the Syringe?

Expel air bubbles before injection by tapping the syringe barrel and pushing the plunger until liquid appears at the needle tip—air displaces liquid volume, so a 10-tick draw with a 2-tick air bubble delivers only 8 ticks of actual peptide solution. At 2.5mg/mL concentration, that's a 50mcg underdose on a 250mcg target. Air bubbles larger than 1 tick (0.01mL) are visible and correctable—smaller microbubbles clinging to the syringe wall are harder to detect but collectively displace 0.005–0.01mL, causing 5–10% dose variation.

What If My Reconstituted Solution Looks Cloudy?

Cloudiness after gentle swirling indicates incomplete dissolution or peptide aggregation—do not inject. Refrigerate the vial for 15–20 minutes, then swirl again gently. If clarity doesn't improve, the batch may have been exposed to temperature excursion during shipping or storage, causing irreversible protein denaturation. Lyophilised BPC-157 stored above 25°C for more than 48 hours shows measurable aggregation in spectroscopic analysis—once aggregated, the peptide cannot be 'fixed' by additional mixing time.

What If I'm Switching Reconstitution Volumes Mid-Protocol?

Recalculate your dose in ticks for the new concentration before drawing—switching from 2mL to 1mL reconstitution doubles your peptide concentration, meaning the same 10-tick draw now delivers twice the BPC-157 mass. A 250mcg dose at 2.5mg/mL concentration (2mL reconstitution) requires 10 ticks. The same 250mcg dose at 5mg/mL concentration (1mL reconstitution) requires only 5 ticks. Failing to adjust tick count when changing concentrations is the most common cause of accidental dose doubling in multi-vial protocols.

The Unforgiving Truth About BPC-157 Dosing Precision

Here's the honest answer: if you're eyeballing syringe ticks or assuming 'close enough' dosing, your protocol consistency is gone. Research-grade work doesn't tolerate 20% dose variation between administrations—yet that's exactly what happens when reconstitution math is skipped, air bubbles aren't expelled, or vial concentration isn't verified before each draw. The difference between a well-controlled study and unreliable data often comes down to whether the researcher treated reconstitution as a precision step or an afterthought.

We mean this sincerely: the peptide's therapeutic potential in your study is conditional on accurate dosing. BPC-157's dose-response curve in preclinical models shows that 250mcg daily produces measurably different outcomes than 400mcg daily—but if your 'standard dose' varies by 30% between injections because reconstitution concentration wasn't calculated correctly, you're not testing BPC-157's effects at a controlled dose. You're testing whatever random dose the syringe happened to deliver that day.

Storage and Stability Impact on Syringe Dosing

Reconstituted BPC-157 in bacteriostatic water maintains stability for 28 days when refrigerated at 2–8°C—beyond that window, peptide degradation accelerates. Studies using HPLC (high-performance liquid chromatography) show that BPC-157 solutions stored at room temperature (20–25°C) lose approximately 8–12% potency per week, while refrigerated solutions show <3% degradation over four weeks. This means a vial reconstituted on day one and used on day 35 delivers roughly 10–15% less active peptide per tick than it did initially—even if the drawn volume remains identical.

Freezing reconstituted peptide solutions is not recommended. The freeze-thaw cycle causes ice crystal formation that disrupts peptide tertiary structure—while the amino acid sequence remains intact, the bioactive conformation may be altered. Lyophilised (freeze-dried) peptides tolerate freezing because water has already been removed, but once reconstituted, the peptide exists in solution where ice formation introduces mechanical stress.

Light exposure accelerates peptide oxidation. BPC-157 vials should be stored in their original amber glass or wrapped in aluminium foil to block UV and visible light. Peptides left on a benchtop under fluorescent lighting for 6–8 hours show measurable oxidative modifications at methionine and cysteine residues—these changes may not affect gross solubility but can reduce biological activity by 10–20%.

Our experience working with researchers on peptide stability: the vial stored correctly in the fridge for three weeks outperforms the vial left at room temperature for three days. Temperature discipline isn't optional—it's the difference between a controlled variable and a confounding one.

If your protocol uses BPC-157 in research models and demands precision dosing, explore our high-purity research peptides. Every batch undergoes small-batch synthesis with exact amino-acid sequencing, ensuring the concentration you calculate during reconstitution matches the peptide mass you're actually delivering per syringe tick.

Reconstitution precision determines whether your BPC-157 IU per tick insulin syringe delivers the intended dose—or introduces 20–30% variation that undermines protocol consistency. The math is simple, the execution is unforgiving, and the difference between accurate and approximate dosing shows up in your data whether you account for it or not.

References

Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.

  1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
  2. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
  3. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
  4. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
  5. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
  6. BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
  7. Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
  8. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The micrograms of BPC-157 per tick depend entirely on your reconstitution concentration. If you reconstitute 5mg BPC-157 in 2mL bacteriostatic water, the concentration is 2.5mg/mL—each 1 IU tick (0.01mL) contains 25mcg of peptide. If you use 1mL of water instead, the concentration doubles to 5mg/mL, and each tick delivers 50mcg. Calculate your specific dose using the formula: (total mg ÷ reconstitution mL) × 0.01mL per tick.
Not for research doses in the 200–500mcg range—3mL syringes have graduation increments of 0.1mL (ten times wider than insulin syringes), making sub-0.1mL measurements impractical. A 250mcg dose at 2.5mg/mL concentration is only 0.1mL, which is the smallest readable division on a 3mL syringe. Insulin syringes provide 0.01mL graduations, allowing precise measurement down to 25mcg increments. Additionally, 3mL Luer-lock syringes have 0.02–0.05mL dead space that causes significant dose loss.
Sterile water for injection (SWFI) lacks the 0.9% benzyl alcohol preservative found in bacteriostatic water, meaning the reconstituted solution must be used within 24 hours to prevent bacterial contamination. Bacteriostatic water inhibits bacterial growth for 28 days, making it suitable for multi-dose vials. If your protocol requires only a single dose, sterile water is acceptable—but for multi-dose use, bacteriostatic water is the standard to prevent contamination risk with each needle puncture.
Visual indicators include cloudiness, colour change (from clear to yellow or amber), or visible particles that don’t dissolve with gentle swirling. Properly reconstituted BPC-157 in bacteriostatic water should remain clear and colourless when refrigerated at 2–8°C for up to 28 days. Beyond that window, peptide degradation accelerates—HPLC analysis shows 8–12% potency loss per week at room temperature and <3% loss over four weeks when refrigerated. If you're past 30 days from reconstitution or the solution appears cloudy, discard it.
Because reconstitution concentration varies between vials based on how much bacteriostatic water you add. A 5mg vial mixed with 2mL yields 2.5mg/mL—10 ticks delivers 250mcg. The same 5mg vial mixed with 1mL yields 5mg/mL—10 ticks now delivers 500mcg (double the dose). If you’re using multiple vials across a protocol, you must recalculate your dose in ticks each time you reconstitute a new vial unless you maintain identical reconstitution volumes every time.
Not recommended—once drawn into the syringe, the peptide solution is exposed to air and loses the sterile sealed environment of the vial. Peptides in syringes degrade faster than in sealed vials due to increased surface-area-to-volume ratio and potential oxidation. Best practice is to draw immediately before injection. If pre-drawing is unavoidable, cap the needle, wrap the syringe in foil to block light, refrigerate at 2–8°C, and use within 12 hours.
A 1mL insulin syringe holds 100 IU total with 1 IU graduations (0.01mL per tick), while a 0.5mL syringe holds 50 IU with 0.5 IU graduations (0.005mL per tick). The 0.5mL syringe offers twice the precision for ultra-low doses but has half the capacity, limiting its use to high-concentration solutions (>5mg/mL). For most BPC-157 research protocols at 2.5–5mg/mL concentration and 200–500mcg doses, the 1mL syringe is optimal—its graduation spacing balances precision and readability.
Decide your target dose in micrograms, then choose a tick count that falls within 8–20 ticks for easy syringe reading. Divide your target dose by your chosen tick count to get micrograms per tick, then solve for reconstitution volume using the formula: reconstitution mL = (total peptide mg × 1000) ÷ (mcg per tick × 100). Example: for 250mcg in 10 ticks, you need 25mcg per tick. With a 5mg vial: (5 × 1000) ÷ (25 × 100) = 2mL reconstitution volume.
No—insulin syringes are single-use devices. Reusing needles dulls the tip, increasing tissue trauma and injection pain while introducing contamination risk. Each needle puncture through a vial stopper deposits microscopic rubber particles and bacteria from the previous puncture site back into the vial. For multi-dose protocols, use a fresh sterile syringe for every draw. The cost difference between single-use and reuse is negligible compared to the contamination risk and reduced injection comfort.
Small subcutaneous air injections (0.01–0.05mL) are generally harmless—air introduced into adipose tissue dissipates without entering the bloodstream. However, injecting air reduces the actual peptide dose delivered because air displaces liquid volume in the syringe. If you injected a 10-tick draw with a 2-tick air bubble, you delivered only 8 ticks of solution (a 20% underdose). To prevent this, always expel air bubbles before injection by tapping the syringe and pushing the plunger until liquid appears at the needle tip.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now